MA27716A1 - 4-aminopyrimidine-5-one - Google Patents

4-aminopyrimidine-5-one

Info

Publication number
MA27716A1
MA27716A1 MA28472A MA28472A MA27716A1 MA 27716 A1 MA27716 A1 MA 27716A1 MA 28472 A MA28472 A MA 28472A MA 28472 A MA28472 A MA 28472A MA 27716 A1 MA27716 A1 MA 27716A1
Authority
MA
Morocco
Prior art keywords
compounds
cancer
preparation
treatment
control
Prior art date
Application number
MA28472A
Other languages
English (en)
Inventor
Chu Xin-Jie
Ding Qingjie
Jiang Nan
John Lovey Allen
Anthony Moliterni John
John Guilfoyle Mullin Jr
Thanh Vu Binh
Michael Wovkulich Peter
Joseph Bartkovitz David
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA27716A1 publication Critical patent/MA27716A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention a trait à de nouveaux dérivés de 4-aminopyrimidine-5-one de formule (I), dans laquelle R1 et R2 sont tels que définis dans la description. Ces composés sont inhibiteurs de la kinase dépendante des cyclines, notamment de la kinase 4 dépendante des cyclines (Cdk4). Ces composés et leurs sels et esters pharmaceutiquement acceptables présentent une activité antiproliférative et sont utiles dans le traitement ou le contrôle du cancer, en particulier des tumeurs solides. La présente invention a également trait à des compositions pharmaceutiques contenant de tels composés, leur utilisation pour le traitement et le contrôle du cancer, à leur procédé de préparation et à des intermédiaires utiles dans leur préparation.
MA28472A 2003-02-10 2005-08-30 4-aminopyrimidine-5-one MA27716A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44627303P 2003-02-10 2003-02-10
US51492603P 2003-10-28 2003-10-28

Publications (1)

Publication Number Publication Date
MA27716A1 true MA27716A1 (fr) 2006-01-02

Family

ID=32853425

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28472A MA27716A1 (fr) 2003-02-10 2005-08-30 4-aminopyrimidine-5-one

Country Status (22)

Country Link
US (2) US7157455B2 (fr)
EP (1) EP1628619A2 (fr)
JP (1) JP2006523183A (fr)
KR (1) KR100717099B1 (fr)
AR (1) AR043693A1 (fr)
AU (1) AU2004210408A1 (fr)
BR (1) BRPI0407381A (fr)
CA (1) CA2512915A1 (fr)
CL (1) CL2004000226A1 (fr)
EA (1) EA009412B1 (fr)
EC (1) ECSP055958A (fr)
HR (1) HRP20050689A2 (fr)
IL (1) IL169626A0 (fr)
MA (1) MA27716A1 (fr)
MX (1) MXPA05008333A (fr)
MY (1) MY137555A (fr)
NO (1) NO20053410L (fr)
PL (1) PL382309A1 (fr)
RS (1) RS20050610A (fr)
TN (1) TNSN05188A1 (fr)
TW (1) TWI293881B (fr)
WO (1) WO2004069139A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7211576B2 (en) * 2004-04-20 2007-05-01 Hoffmann-La Roche Inc. Diaminothiazoles
US7405220B2 (en) 2004-06-09 2008-07-29 Hoffmann-La Roche Inc. Pyrazolopyrimidines
ATE405828T1 (de) * 2005-05-25 2008-09-15 Hoffmann La Roche Biomarker zur reaktionsüberwachung von cdk- hemmern in der klinik
US7705009B2 (en) * 2005-11-22 2010-04-27 Hoffman-La Roche Inc. 4-aminopyrimidine-5-thione derivatives
KR20100129331A (ko) 2005-12-01 2010-12-08 에프. 호프만-라 로슈 아게 항암제로서 사용하기 위한 ｐ53 및 ｍｄｍ2 단백질 간 상호작용의 저해제로서의 2,4,5-트리페닐 이미다졸린 유도체
WO2007113005A2 (fr) * 2006-04-03 2007-10-11 European Molecular Biology Laboratory (Embl) Inhibiteurs de la kinase aurora
WO2010019967A1 (fr) * 2008-08-15 2010-02-18 Georgetown University Inhibiteurs de cdk fluorescents pour le traitement du cancer
AR081331A1 (es) * 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
EP2560488B1 (fr) 2010-04-23 2015-10-28 Cytokinetics, Inc. Aminopyridines et aminotriazines, leurs compositions et leurs procédés d'utilisation
HUE045748T2 (hu) * 2014-07-01 2020-01-28 Millennium Pharm Inc Heteroaril vegyületek mint SUMO aktiváló enzimek inhibitorai
EP3981765A4 (fr) * 2019-06-06 2023-05-31 Beijing Tide Pharmaceutical Co., Ltd. Antagoniste du récepteur p2x3 et/ou p2x2/3, composition pharmaceutique le contenant et son utilisation
CN116472270B (zh) * 2021-02-05 2025-07-15 上海齐鲁制药研究中心有限公司 Cdk抑制剂
AU2023345059A1 (en) * 2022-09-22 2025-04-10 Joint Stock Company «Biocad» Cyclin-dependent kinase 7 inhibitors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9012592D0 (en) 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
KR20000070751A (ko) * 1997-02-05 2000-11-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 세포 증식 억제제로서의 피리도[2,3-ｄ]피리미딘 및 4-아미노피리미딘
UA66810C2 (uk) 1997-10-27 2004-06-15 Агорон Фармацевтикалз Інк. Похідні 4-амінотіазолу та композиції на їх основі як інгібітори циклінозалежних кіназ
US6262096B1 (en) * 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
JP2002503662A (ja) 1998-02-17 2002-02-05 テュラリク インコーポレイテッド 抗ウイルス性ピリミジン誘導体
DE69933680T2 (de) 1998-08-29 2007-08-23 Astrazeneca Ab Pyrimidine verbindungen
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
KR20020027649A (ko) 1999-09-15 2002-04-13 로즈 암스트롱, 크리스틴 에이. 트러트웨인 카이나제 억제제로서의 프테리딘온
EP1235815A1 (fr) 1999-11-22 2002-09-04 Warner-Lambert Company Quinazolines et leur utilisation dans l'inhibition des enzymes kinase dependant de la cycline
WO2001055147A1 (fr) * 2000-01-25 2001-08-02 Warner-Lambert Company Inhibiteurs de pyrido[2,3-d]pyrimidine-2,7-diamine kinase
CZ20022521A3 (cs) * 2000-01-27 2003-02-12 Warner-Lambert Company Pyridopyrimidinonové deriváty pro léčení neurodegenerativních onemocnění
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
BR0110302A (pt) 2000-04-18 2003-01-14 Agouron Pharma Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase
ES2266258T3 (es) * 2000-09-15 2007-03-01 Vertex Pharmaceuticals Incorporated Compuestos de pirazol utiles como inhibidores de proteina cinasas.
EP1345925B1 (fr) * 2000-12-21 2006-05-17 Vertex Pharmaceuticals Incorporated Composes de pyrazole presentant une grande utilite comme inhibiteurs de proteine kinase
AU2002312933B2 (en) * 2001-05-29 2007-12-06 Schering Ag CDK inhibiting pyrimidines, production thereof and their use as medicaments
US7288547B2 (en) * 2002-03-11 2007-10-30 Schering Ag CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents
KR20050084027A (ko) 2002-11-28 2005-08-26 쉐링 악티엔게젤샤프트 Ｃｈｋ-, ｐｄｋ- 및 ａｋｔ-억제성 피리미딘, 그의제조방법 및 약제로서의 그의 용도
EP1605942A1 (fr) 2003-02-10 2005-12-21 Pfizer Inc. Schema posologique pour nelfinavir
NZ541681A (en) * 2003-02-10 2009-02-28 Bayer Healthcare Ag Treatment of bacterial diseases of the respiratory organs by locally applying ciprofloxacin and its salts
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel

Also Published As

Publication number Publication date
JP2006523183A (ja) 2006-10-12
KR100717099B1 (ko) 2007-05-10
EA009412B1 (ru) 2007-12-28
BRPI0407381A (pt) 2006-02-07
TNSN05188A1 (en) 2007-06-11
CA2512915A1 (fr) 2004-08-19
MXPA05008333A (es) 2005-09-30
AR043693A1 (es) 2005-08-10
US20060229330A1 (en) 2006-10-12
US20040162303A1 (en) 2004-08-19
WO2004069139A2 (fr) 2004-08-19
TWI293881B (en) 2008-03-01
RS20050610A (sr) 2007-12-31
EA200501233A1 (ru) 2006-04-28
NO20053410L (no) 2005-09-08
PL382309A1 (pl) 2007-08-20
WO2004069139A3 (fr) 2007-04-26
CL2004000226A1 (es) 2005-01-14
KR20050099544A (ko) 2005-10-13
US7615634B2 (en) 2009-11-10
HRP20050689A2 (hr) 2006-08-31
EP1628619A2 (fr) 2006-03-01
TW200423940A (en) 2004-11-16
US7157455B2 (en) 2007-01-02
MY137555A (en) 2009-02-27
ECSP055958A (es) 2006-01-16
IL169626A0 (en) 2007-07-04
AU2004210408A1 (en) 2004-08-19

Similar Documents

Publication Publication Date Title
MA27568A1 (fr) Derives de pyrrolopyrimidine
TNSN04156A1 (fr) Pyridinones substituees servant de modulateurs de la map-kinase p38
MA28747B1 (fr) Dérivés de pyridine
TNSN05250A1 (fr) Pyrimidinones substituees
TNSN04246A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
MA29926B1 (fr) Derives de pyrazine
MA26727A1 (fr) Derives nouveaux de pyrimidine inhibiteurs de sorbitol deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
TNSN05298A1 (fr) Derives de pyrazolo-quinazoline, procede pour leur preparation et leur utilisation comme inhibiteurs de kinases
MA26733A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA27775A1 (fr) Composes organiques
MA30075B1 (fr) Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale
RU2203274C2 (ru) Спироциклические ингибиторы металлопротеаз
MA56883B1 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
TNSN05073A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
MA30142B1 (fr) Agonistes du recepteur de neuropeptide-2
MA26956A1 (fr) Pyrimidine-2,4,6,triones inhibitrices de metalloproteinases.
TN2009000450A1 (fr) Derives de pyridine
TNSN08445A1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
MA28064A1 (fr) Dérivés de pyrrolo [3,4-c] pyrazole actifs comme inhibiteurs de kinases
MA27703A1 (fr) Derives de diazepino-indole servant d'inhibiteurs de kinases
MA31754B1 (fr) Cis-imidazolines chirales
EP1689713A4 (fr) Inhibiteurs de benzylether et benzylamino de beta-secretase pour traiter la maladie d'alzheimer